A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 Coinfection

NCT01939197 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

318

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C Virus Infection
Human Immunodeficiency Virus Infection
Chronic Hepatitis C
Compensated Cirrhosis and Non-cirrhotics

Interventions

DRUG: ABT-450/r/ABT-267
DRUG: ABT-333
DRUG: ribavirin

Sponsor

AbbVie